MA-PTC
13.8.2019 15:02:06 CEST | Business Wire | Press release
PTC (NASDAQ: PTC) today announced it has been named a leader in the Industrial IoT (IIoT) platform market in a new research report from IDC entitled “IDC MarketScape: Worldwide Industrial IoT Platforms in Manufacturing 2019 Vendor Assessment ” (doc #US45116819e June 2019). IDC MarketScape positions PTC as a leader in the IIoT platforms market worldwide. The ThingWorx® IIoT platform is the core of PTC’s technology portfolio, designed to provide industrial companies with the functionality and flexibility they need to transform the way they design, manufacture, and operate for a smart, connected world.
The IDC MarketScape report examines the capabilities and strategies of PTC and 11 other IIoT platform vendors. Each company was evaluated and assessed according to a wide-ranging set of criteria, including: the robustness of the offering, the company’s go-to-market approach, and the stability and viability of the business.
The report highlighted PTC’s strengths, stating that “PTC's software portfolio has the ability to support the integration, unification, and decision support of data, processes, resources, and people.” The report further notes PTC’s product portfolio, stating that it is “well-aligned to deliver on the vendor's vision within the manufacturing space.”
PTC’s ThingWorx industrial innovation solutions platform is the centerpiece of its IIoT technology portfolio. Comprised of a rapid application development platform, device connectivity, machine learning capabilities, augmented reality, and integration with leading device clouds, ThingWorx delivers a comprehensive IIoT technology stack that enables customers to securely connect assets, quickly create applications and experiences, and innovate new ways to capture value.
Specialized IIoT Solutions
PTC offers a wide range of solutions
that extend the ThingWorx platform with packaged capabilities based on the most common use cases found in industrial settings. These platform capabilities help drive greater productivity, efficiency, and agility in industrial operations.
Powerful Strategic Alliances
Throughout the past year, in addition to enhancing the platform with new capabilities and rolling out a range of use-case specific solutions, PTC deepened its strategic alliances with Rockwell Automation
, Microsoft
, and ANSYS
to advance its go-to-market initiatives.
“We recognize PTC as a leader for Industrial IoT platform vendors worldwide.” said Stacy Crook, research director, IDC’s Internet of Things Ecosystem and Trends. “The company’s ThingWorx platform addresses manufacturers’ digital transformation priorities, and combined with PTC’s strategic alliances, enables customers to succeed in their IoT journeys.”
“We are delighted that the IDC MarketScape report has recognized the power of our platform and the breadth of our market presence,” said Jim Heppelmann, president and CEO, PTC. “This report is a testament to our ThingWorx IIoT platform, corporate strategy, comprehensive road map, key strategic alliances, and commitment to helping our industrial customers excel in their digital transformation initiatives.”
About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of ICT (information and communications technology) suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.
About PTC (NASDAQ: PTC)
PTC unleashes industrial innovation with award-winning, market-proven solutions that enable companies to differentiate their products and services, improve operational excellence, and increase workforce productivity. With PTC, and its partner ecosystem, manufacturers can capitalize on the promise of today’s new technology to drive digital transformation.
PTC, ThingWorx, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190813005441/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom